<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5763">
  <stage>Registered</stage>
  <submitdate>10/11/2015</submitdate>
  <approvaldate>10/11/2015</approvaldate>
  <nctid>NCT02604355</nctid>
  <trial_identification>
    <studytitle>A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients</studytitle>
    <scientifictitle>A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose, Adaptive Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Subjects and Chronic Hepatitis B Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BP29948</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Matching Placebo
Treatment: drugs - RO7020322

Experimental: Healthy Participants (Multiple-Ascending Dosing) - 

Experimental: Healthy Participants (Single-Ascending Dosing) - 

Experimental: Healthy Participants (Study of Food Effect) - 

Experimental: Participants with Chronic Hepatitis B (Proof of mechanism) - 


Other interventions: Matching Placebo
Oral dosing with placebo capsules to match RO7020322.

Treatment: drugs: RO7020322
Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Intensity of adverse events</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant laboratory abnormalities</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant electrocardiogram (ECG) abnormalities</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant vital signs abnormalities</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma concentration (Cmax) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time from dosing to Cmax (Tmax) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough plasma concentrations (Ctrough) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve between time zero (pre-dose) and the time of the last quantifiable concentration (AUClast) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve between time zero (pre-dose) extrapolated to infinity (AUC0-Inf) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent clearance (CL/F) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent volume (V/F) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent terminal phase half-life (t1/2) of RO7020322</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve (AUC0-t,ss) of RO7020322 at steady state</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve (AUC0-t) of RO7020322 on Day 1</outcome>
      <timepoint>Up to 18 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of hepatitis B surface antigen (HBsAg)</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy Participants' 

          -  A Body Mass Index (BMI) between 18 to 30 kg/m^2, inclusive, and a body weight of at
             least 50 kg

          -  Males must agree to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agree to refrain from donating sperm during the study

          -  Women should be of non-childbearing potential

          -  Able to comply with study restrictions

          -  Non-smoker (nor tobacco-containing products) for at least 90 days prior to dosing on
             Day 1 and agreeing not to smoke during the study

        Chronic Hepatitis B-Infected Participants' 

          -  Chronic hepatitis B infection

          -  A BMI between 18 to 32 kg/m^2, inclusive

          -  Positive test for HBsAg for more than 6 months prior to randomization

          -  On entecavir or tenofovir treatment for at least 6 months prior to randomization and
             remaining on stable treatment during the study

          -  Liver biopsy, fibroscanÂ® or equivalent test obtained within the past 6 months
             demonstrating liver disease consistent with chronic hepatitis B (HBV) infection
             without evidence of bridging fibrosis or cirrhosis

          -  Males must agree to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agree to refrain from donating sperm during the study

          -  Women of childbearing potential must agree to remain abstinent (refrain from
             heterosexual intercourse) or use non-hormonal contraceptive methods that result in a
             failure rate of &lt; 1% per year during the treatment period and for at least until the
             end of the follow-up period</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Healthy Participants' 

          -  Women who are lactating

          -  Any suspicion or history of alcohol and/or other substance abuse or dependence in the
             past 6 months

          -  Positive urine drug and alcohol screen (barbiturates, benzodiazepines, methadone,
             amphetamines, methamphetamines, opiates, cocaine, cannabinoids, and alcohol), or
             positive cotinine test at Day -1

          -  Positive result on HBV, hepatitis C (HCV), or human immunodeficiency virus (HIV) 1 and
             2

          -  A personal history of unexplained blackouts or faints, or known risk factors for
             Torsade de Pointes

          -  Clinically significant abnormalities (as judged by the Investigator) in the physical
             examination and in the laboratory test results (including hepatic and renal panels,
             complete blood count, chemistry panel and urinalysis) at screening and on Day -1

          -  Participation in an investigational drug or device study within 90 days prior to
             screening or 5 times the half-life of the investigational drug (whichever is longer)

          -  Donation of blood over 500 mL within three months prior to screening

          -  Concomitant disease or condition (including allergic reactions against any drug, or
             multiple allergies) that could interfere with, or treatment of which might interfere
             with, the conduct of the study, or that would, in the opinion of the Investigator,
             pose an unacceptable risk to the healthy participant in this study

        Chronic Hepatitis B-Infected Participants' 

          -  Women who are pregnant (positive pregnancy test) or lactating

          -  History or other evidence of bleeding from esophageal varices

          -  Decompensated liver disease

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HBV infection

          -  Documented history or other evidence of metabolic liver disease within one year of
             randomization

          -  Positive test for hepatitis A (IgM anti-HAV), hepatitis C, or HIV

          -  Documented history of infection with hepatitis D virus

          -  Expected to need systemic antiviral therapy other than that provided by the study at
             any time during their participation in the study, with the exception of oral therapy
             for herpes simplex virus (HSV) I or HSV II

          -  History of immunologically-mediated disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>28/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>49</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>9/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multiple-center, randomized, double-blind, placebo-controlled, single-ascending
      dose and multiple-ascending dose, adaptive parallel study to investigate the safety,
      tolerability, pharmacokinetics and pharmacodynamics of RO7020322 following oral
      administration in healthy participants and chronic hepatitis B patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02604355</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>